Physician profile
Mark E Gillespie
NPI 1942277280
$5,031.81
in general payments reported to CMS, 2019-2025
27 companies · $944 in 2025
The $944 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936 · 2020: $317 · 2021: $443 · 2022: $519 · 2023: $481 · 2024: $392 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,274.87 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Aerie Pharmaceuticals, INC. | $776.06 | 2019-2021 | |
| Abbvie INC. | $391.17 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $363.15 | 2022-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Allergan, INC. | $296.75 | 2019-2021 | |
| Rxsight INC | $285.14 | 2022-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $214.99 | 2019-2021 | |
| Ocular Therapeutix, INC. | $185.91 | 2025 | Dextenza |
| Shire North American Group INC | $179.65 | 2019 | |
| Bausch & Lomb Americas INC. | $144.92 | 2022-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Neurotech Pharmaceuticals, INC. | $137.39 | 2025 | |
| Sun Pharmaceutical Industries INC. | $133.65 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $117.93 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $105.69 | 2020-2022 | |
| Biotissue Holdings INC. | $52.07 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $50.30 | 2023-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Astellas Pharma US INC | $46.29 | 2023-2024 | Izervay |
| Harrow Eye, LLC | $45.00 | 2025 | Vevye |
| Genentech USA, INC. | $41.34 | 2019-2021 | |
| Glaukos Corporation | $32.44 | 2024 | Idose |
| Sight Sciences, INC. | $30.05 | 2021-2023 | Omni Surgical System |
| Catalyst Pharmaceuticals, INC. | $29.51 | 2025 | |
| Dompe US, INC. | $26.79 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $21.21 | 2025 | Xdemvy |
| Alexion Pharmaceuticals, INC. | $19.43 | 2025 | Ultomiris |
| Amgen INC. | $15.34 | 2025 | Tavneos |
| Lombart Brothers, INC. | $14.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.